Why Does Liraglutide Work Less Well for Weight Loss After Bariatric Surgery?

Patients with prior metabolic surgery were nearly 7 times less likely to achieve successful weight loss with liraglutide compared to those without surgical history.

Ouyang, Yuqin et al.·Frontiers in endocrinology·2025·Preliminary EvidenceRetrospective Cohort
RPEP-12899Retrospective CohortPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Retrospective Cohort
Evidence
Preliminary Evidence
Sample
N=64
Participants
N=64 adults with mild obesity (BMI 28-32.5), about 76% female, treated with liraglutide for 12 weeks.

What This Study Found

Prior metabolic surgery was associated with a 6.78x higher odds of poor response to liraglutide for weight loss.

Key Numbers

  • 64 adults, BMI 28-32.5, 12-week liraglutide treatment
  • Responders: 37 (57.8%); non-responders: 27 (42.2%)
  • Responder weight loss: 11.0% (9.04 kg) vs non-responder: 4.2% (3.55 kg)
  • Prior metabolic surgery: OR 6.78 for non-response (95% CI 1.95-23.61, p<0.01)
  • BMI 30.5+: OR 4.79 for non-response (95% CI 1.46-15.71, p<0.01)

How They Did This

Retrospective analysis of 64 adults with mild obesity on a 12-week liraglutide intervention.

Why This Research Matters

As more patients have histories of both bariatric surgery and GLP-1 medication use, understanding interactions between these approaches is critical for treatment planning.

The Bigger Picture

With the growing overlap between surgical and pharmacological obesity treatments, clinicians need to understand which patients are most likely to benefit from each approach.

What This Study Doesn't Tell Us

Small sample size (64 patients). Retrospective design. Short 12-week duration. No details on type of prior metabolic surgery.

Questions This Raises

  • ?What mechanisms explain reduced liraglutide efficacy after bariatric surgery?
  • ?Would tirzepatide or semaglutide show similar reduced efficacy in this population?

Trust & Context

Key Stat:
6.78x Higher odds of poor response to liraglutide in patients with prior metabolic surgery
Evidence Grade:
Small retrospective study. Low evidence quality but important clinical signal warranting further investigation.
Study Age:
Published in 2025.
Original Title:
Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.
Published In:
Frontiers in endocrinology, 16, 1580159 (2025)
Database ID:
RPEP-12899

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Looks back at existing records to find patterns.

What do these levels mean? →

Frequently Asked Questions

Does prior bariatric surgery affect GLP-1 medication effectiveness?

This study found that patients with prior metabolic surgery were nearly 7 times less likely to achieve successful weight loss with liraglutide.

Should post-surgical patients still try GLP-1 drugs?

They may still benefit, but expectations should be adjusted. Alternative strategies or combination approaches may be more appropriate.

Read More on RethinkPeptides

Cite This Study

RPEP-12899·https://rethinkpeptides.com/research/RPEP-12899

APA

Ouyang, Yuqin; Xiang, Xinyue; Hu, Xinyun; Chu, Xuehui; Tang, Wenjuan; Feng, Wenhuan. (2025). Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.. Frontiers in endocrinology, 16, 1580159. https://doi.org/10.3389/fendo.2025.1580159

MLA

Ouyang, Yuqin, et al. "Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.." Frontiers in endocrinology, 2025. https://doi.org/10.3389/fendo.2025.1580159

RethinkPeptides

RethinkPeptides Research Database. "Prior metabolic surgery attenuates the weight-loss efficacy ..." RPEP-12899. Retrieved from https://rethinkpeptides.com/research/ouyang-2025-prior-metabolic-surgery-attenuates

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.